These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 34357147)

  • 1. Parkinson's Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors.
    Metta V; Batzu L; Leta V; Trivedi D; Powdleska A; Mridula KR; Kukle P; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
    Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA
    Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
    Antonini A; Nitu B
    J Neural Transm (Vienna); 2018 Aug; 125(8):1131-1135. PubMed ID: 30006821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile.
    Leta V; Dafsari HS; Sauerbier A; Metta V; Titova N; Timmermann L; Ashkan K; Samuel M; Pekkonen E; Odin P; Antonini A; Martinez-Martin P; Parry M; van Wamelen DJ; Ray Chaudhuri K
    J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infusion Therapies for Parkinson's Disease.
    Prakash N; Simuni T
    Curr Neurol Neurosci Rep; 2020 Aug; 20(9):44. PubMed ID: 32740768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience.
    Metta V; Dhamija RK; Batzu L; Mrudula R; Kumar NSS; S A; Falup-Pecurariu C; Rodriguez-Blazquez C; Goyal V; L K P; Bhattacharya K; Kumar S; Chaudhuri KR; Borgohain R
    Sci Rep; 2023 Oct; 13(1):18681. PubMed ID: 37907679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.
    Odin P; Ray Chaudhuri K; Slevin JT; Volkmann J; Dietrichs E; Martinez-Martin P; Krauss JK; Henriksen T; Katzenschlager R; Antonini A; Rascol O; Poewe W;
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1133-44. PubMed ID: 26233582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile Of Patients With Advanced Parkinson's disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients.
    Szász JA; Constantin VA; Orbán-Kis K; Rácz A; Bancu LA; Georgescu D; Szederjesi J; Mihály I; Fárr AM; Kelemen K; Vajda T; Szatmári S
    Neuropsychiatr Dis Treat; 2019; 15():3187-3195. PubMed ID: 32009788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Device-aided therapies in advanced Parkinson's disease].
    Timofeeva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson's Disease: A Systematic Review.
    Gaire S; Kafle S; Bastakoti S; Paudel A; Karki K
    Cureus; 2021 Sep; 13(9):e17949. PubMed ID: 34660137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
    Catalán MJ; Antonini A; Calopa M; Băjenaru O; de Fábregues O; Mínguez-Castellanos A; Odin P; García-Moreno JM; Pedersen SW; Pirtošek Z; Kulisevsky J
    eNeurologicalSci; 2017 Sep; 8():44-53. PubMed ID: 29260038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
    Guthikonda LN; Lyons KE; Pahwa R
    J Comp Eff Res; 2014 Jul; 3(4):331-3. PubMed ID: 25275230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Device-Aided Therapies in Parkinson's Disease-Results from the German Care4PD Study.
    Fründt O; Hanff AM; Möhl A; Mai T; Kirchner C; Amouzandeh A; Buhmann C; Krüger R; Südmeyer M
    Brain Sci; 2023 Apr; 13(5):. PubMed ID: 37239208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
    Trenkwalder C; Chaudhuri KR; García Ruiz PJ; LeWitt P; Katzenschlager R; Sixel-Döring F; Henriksen T; Sesar Á; Poewe W; ; Baker M; Ceballos-Baumann A; Deuschl G; Drapier S; Ebersbach G; Evans A; Fernandez H; Isaacson S; van Laar T; Lees A; Lewis S; Martínez Castrillo JC; Martinez-Martin P; Odin P; O'Sullivan J; Tagaris G; Wenzel K
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1023-30. PubMed ID: 26189414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.
    Antonini A
    J Mov Disord; 2009 May; 2(1):4-9. PubMed ID: 24868344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced therapies in Parkinson's disease: an individualized approach to their indication.
    Schröter N; Sajonz BEA; Jost WH; Rijntjes M; Coenen VA; Groppa S
    J Neural Transm (Vienna); 2024 Nov; 131(11):1285-1293. PubMed ID: 38613674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.